Rockville biotech looks for lifeline following restructuring

Rexahn Pharmaceuticals Inc. is standing at a crossroads. The Rockville biotech announced Tuesday an intention to consider “strategic alternatives” as it cuts staff and searches for ways to extend resources.  Potential moves include a merger or acquisition, reverse merger or other business combination. It could also mean licensing or selling off it s assets. CEO Doug Swirsky declined to comment beyond the company’s press release. Rexahn (NASDAQ: REXN) is also eliminating two positions and…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news